| Literature DB >> 27025858 |
Michela Buglione1, Sara Pedretti2, Pietro Luigi Poliani3, Roberto Liserre4, Stefano Gipponi5, Giannantonio Spena6, Paolo Borghetti2, Ludovica Pegurri2, Federica Saiani7, Luigi Spiazzi7, Giulia Tesini7, Chiara Uccelli7, Luca Triggiani2, Stefano Maria Magrini2.
Abstract
To analyse the pattern of recurrence of patients treated with Stupp protocol in relation to technique, to compare in silico plans with reduced margin (1 cm) with the original ones and to analyse toxicity. 105 patients were treated: 85 had local recurrence and 68 of them were analysed. Recurrence was considered in field, marginal and distant if >80 %, 20-80 % or <20 % of the relapse volume was included in the 95 %-isodose. In silico plans were retrospectively recalculated using the same technique, fields angles and treatment planning system of the original ones. The pattern of recurrence was in field, marginal and distant in 88, 10 and 2 % respectively and was similar in in silico plans. The margin reduction appears to spare 100 cc of healthy brain by 57 Gy-volume (p = 0.02). The target coverage was worse in standard plans (pt student < 0.001), especially if the tumour was near to organs at risk (pχ2 < 0.001). PTV coverage was better with IMRT and helical-IMRT, than conformal-3D (pAnova test = 0.038). This difference was no more significant with in silico planning. A higher incidence of asthenia and leuko-encephalopathy was observed in patients with greater percentage of healthy brain included in 57 Gy-volume. No differences in the pattern of recurrence according to margins were found. The margin reduction determines sparing of healthy brain and could possibly reduce the incidence of late toxicity. Margin reduction could allow to use less sophisticated techniques, ensuring appropriate target coverage, and the choice of more costly techniques could be reserved to selected cases.Entities:
Keywords: Glioblastoma; Margin reduction; Radio-induced late toxicity; Radiotherapy techniques
Mesh:
Year: 2016 PMID: 27025858 DOI: 10.1007/s11060-016-2112-2
Source DB: PubMed Journal: J Neurooncol ISSN: 0167-594X Impact factor: 4.130